<?xml version="1.0" encoding="UTF-8"?><html xmlns:h="http://www.w3.org/1999/xhtml" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
   <div class="article-meta" tagx="article-meta" title="article-meta">
      <span class="pmcid" title="pmcid">
         			pmcid:
         			
         <a href="http://www.ncbi.nlm.nih.gov/pubmed/320490">320490</a>
      </span>
      <span class="publisher-id" title="publisher-id">1475-2832-3-1</span>
      <span class="pmid" title="pmid">
         			pmid:
         			
         <a href="http://www.ncbi.nlm.nih.gov/pubmed/14711381">14711381</a>
      </span>
      <span class="doi" title="doi">
         			doi:
         			
         <a href="https://dx.doi.org/10.1186/1475-2832-3-1">10.1186/1475-2832-3-1</a>
      </span>
      <div class="article-categories" title="article-categories">
         <div xmlns="http://www.w3.org/1999/xhtml"><span>Primary Research</span></div>
      </div>
      <div class="title-group">
         <div xmlns="http://www.w3.org/1999/xhtml">Behavioral and antioxidant activity of a tosylbenz[g]indolamine derivative. A proposed
            better profile for a potential antipsychotic agent
         </div>
      </div>
      <div xmlns="http://www.w3.org/1999/xhtml">
         <span xmlns="" class="contrib" title="contrib">
            <span class="name" tagx="name" title="name"><span xmlns="http://www.w3.org/1999/xhtml">Zika</span><span xmlns="http://www.w3.org/1999/xhtml">Chara A</span></span><a xmlns="http://www.w3.org/1999/xhtml">1</a><span xmlns="http://www.w3.org/1999/xhtml">chzika@pharm.auth.gr</span></span>
         <span xmlns="" class="contrib" title="contrib">
            <span class="name" tagx="name" title="name"><span xmlns="http://www.w3.org/1999/xhtml">Nicolaou</span><span xmlns="http://www.w3.org/1999/xhtml">Ioannis</span></span><a xmlns="http://www.w3.org/1999/xhtml">1</a><span xmlns="http://www.w3.org/1999/xhtml">Inicolao@pharm.auth.gr</span></span>
         <span xmlns="" class="contrib" title="contrib">
            <span class="name" tagx="name" title="name"><span xmlns="http://www.w3.org/1999/xhtml">Gavalas</span><span xmlns="http://www.w3.org/1999/xhtml">Antonis</span></span><a xmlns="http://www.w3.org/1999/xhtml">1</a><span xmlns="http://www.w3.org/1999/xhtml">vdem@pharm.auth.gr</span></span>
         <span xmlns="" class="contrib" title="contrib">
            <span class="name" tagx="name" title="name"><span xmlns="http://www.w3.org/1999/xhtml">Rekatas</span><span xmlns="http://www.w3.org/1999/xhtml">George V</span></span><a xmlns="http://www.w3.org/1999/xhtml">1</a><span xmlns="http://www.w3.org/1999/xhtml">vdem@pharm.auth.gr</span></span>
         <span xmlns="" class="contrib" title="contrib">
            <span class="name" tagx="name" title="name"><span xmlns="http://www.w3.org/1999/xhtml">Tani</span><span xmlns="http://www.w3.org/1999/xhtml">Ekaterini</span></span><a xmlns="http://www.w3.org/1999/xhtml">1</a><span xmlns="http://www.w3.org/1999/xhtml">vdem@pharm.auth.gr</span></span>
         <span xmlns="" class="contrib" title="contrib">
            <span class="name" tagx="name" title="name"><span xmlns="http://www.w3.org/1999/xhtml">Demopoulos</span><span xmlns="http://www.w3.org/1999/xhtml">Vassilis J</span></span><a xmlns="http://www.w3.org/1999/xhtml">1</a><span xmlns="http://www.w3.org/1999/xhtml">vdem@pharm.auth.gr</span></span>
      </div>
      <span class="citation_author_institution" id="I1">[],
         	  <span xmlns="http://www.w3.org/1999/xhtml">1</span></span>
      <span class="pub-date-collection" title="pub-date-collection">collection: 
         <span></span>
      </span>
      <span class="pub-date-epub" title="pub-date-epub">epub: 
         <span></span>
      </span><span xmlns="http://www.w3.org/1999/xhtml">3</span><span xmlns="http://www.w3.org/1999/xhtml">1</span><span xmlns="http://www.w3.org/1999/xhtml">1</span><span xmlns="http://www.w3.org/1999/xhtml"></span><span class="history" title="history">
         <span class="received" title="received">received: --</span>
         <span class="accepted" title="accepted">accepted: --</span>
      </span>
      <div xmlns="http://www.w3.org/1999/xhtml"><span>Copyright Â© 2004 Zika et al; licensee BioMed Central Ltd. This is an Open Access article:
            verbatim copying and redistribution of this article are permitted in all media for
            any purpose, provided this notice is preserved along with the article's original URL.</span><span>2004</span><span>Zika et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim
            copying and redistribution of this article are permitted in all media for any purpose,
            provided this notice is preserved along with the article's original URL.</span></div>
      <div xmlns="http://www.w3.org/1999/xhtml">
         <div xmlns="" class="sec" title="sec">
            <div xmlns="http://www.w3.org/1999/xhtml">Background</div>
            <p xmlns="http://www.w3.org/1999/xhtml">Tardive dyskinesia (TD) is a major limitation of older antipsychotics. Newer antipsychotics
               have various other side effects such as weight gain, hyperglycemia, etc. In a previous
               study we have shown that an indolamine molecule expresses a moderate binding affinity
               at the dopamine D
               <sub>2 </sub>and serotonin 5-HT
               <sub>1A </sub>receptors in in vitro competition binding assays. In the present work, we tested its
               p-toluenesulfonyl derivative (TPBIA) for behavioral effects in rats, related to interactions
               with central dopamine receptors and its antioxidant activity.
               
            </p>
         </div>
         <div xmlns="" class="methods" title="methods">
            <div xmlns="http://www.w3.org/1999/xhtml">Methods</div>
            <p xmlns="http://www.w3.org/1999/xhtml">Adult male Fischer-344 rats grouped as: i) Untreated rats: TPBIA was administered
               i.p. in various doses ii) Apomorphine-treated rats: were treated with apomorphine
               (1 mg kg
               <span>-1</span>, i.p.) 10 min after the administration of TPBIA. Afterwards the rats were placed
               individually in the activity cage and their motor behaviour was recorded for the next
               30 min The antioxidant potential of TPBIA was investigated in the model of in vitro
               non enzymatic lipid peroxidation.
               
            </p>
         </div>
         <div xmlns="" class="sec" title="sec">
            <div xmlns="http://www.w3.org/1999/xhtml">Results</div>
            <p xmlns="http://www.w3.org/1999/xhtml">i) In non-pretreated rats, TPBIA reduces the activity by 39 and 82% respectively,
               ii) In apomorphine pretreated rats, TPBIA reverses the hyperactivity and stereotype
               behaviour induced by apomorphine. Also TPBIA completely inhibits the peroxidation
               of rat liver microsome preparations at concentrations of 0.5, 0.25 and 0.1 mM.
            </p>
         </div>
         <div xmlns="" class="sec" title="sec">
            <div xmlns="http://www.w3.org/1999/xhtml">Conclusion</div>
            <p xmlns="http://www.w3.org/1999/xhtml">TPBIA exerts dopamine antagonistic activity in the central nervous system. In addition,
               its antioxidant effect is a desirable property, since TD has been partially attributed,
               to oxidative stress. Further research is needed to test whether TPBIA may be used
               as an antipsychotic agent.
            </p>
         </div>
      </div>
   </div>
</html>